Figure 3

Comparison of peripheral blood: (A) Th17/Tregs ratio after SAH during EBI and DBI phases with healthy controls; (B) HLA-DR− CD38+ Th17/Tregs ratio after SAH during EBI and DBI phases with healthy controls; (C) HLA-DR− CD38− Th17/Tregs ratio after SAH during EBI and DBI phases with healthy controls; (D) HLA-DR− CD38− Th1/Th2 cells ratio after SAH during EBI and DBI phases with healthy controls; (E) Th1/Th2 cells ratio after SAH in patients with infections and without infections during EBI and DBI phases; (F) HLA-DR− CD38− Th1/Th2 cells ratio (expressed as %age of CD3+ CD4+ T cells) after SAH in patients with infections and without infections during EBI and DBI phases. One way ANOVA followed by Tukey’s multiple comparisons test for normally distributed data. Kruskal Wallis test followed by Dunn’s multiple comparisons test for non-normally distributed data; A p value < 0.05 was considered as a significant difference. *Indicates a p value < 0.05, **indicates a p value < 0.01, ***indicates a p value < 0.001. HC healthy controls (n = 10), EBI early brain injury phase after SAH covering days 1–3 (n = 15), DBI delayed brain injury phase after SAH covering days 7–9 (n = 15).